Introduction
============

Common preservatives used in ophthalmic solutions include benzalkonium chloride (BAK), chlorobutanol, methyl paraoxybenzoate, propyl paraoxybenzoate, and boric acid. The toxicity of these preservatives against ocular surface cells, namely the cornea and conjunctiva, has been investigated extensively[@b1-opth-4-1019]--[@b10-opth-4-1019] because epithelial disorders are of particular concern postoperatively, as well as in patients using eye drops over the longer term, and those with dry eye. In the present study, we examined the toxicity of ophthalmic solutions commonly used after eye surgery to control infection and inflammation in a bioassay using four established ocular surface cell lines. A further aim of the present study was to develop a scoring method of cell viability to enable the easy comparison of drugs, because many toxicity studies use multiple methods to evaluate cell damage and data evaluation consequently becomes complicated.

Material and methods
====================

The commercially available cell lines used in the present study were the SIRC (rabbit corneal epithelium; ATCC CCL-60; American Type Culture Collection (ATCC), Manassas, VA, USA), BCE C/D-1b (bovine corneal epithelial cells; JCRB-9129; Health Science Research Resource Bank, Osaka, Japan), RC-1 (rabbit corneal epithelium; JCRB-0246; Health Science Research Resource Bank) and Chang conjunctiva (human conjunctival cells; ATCC CCL-20.2; ATCC) lines. All cells were cultured according to standard protocols provided by the distributors.

After cells had reached 80%--90% confluence and had been cultured under standard conditions for 48 h, a 100μL aliquot of the culture containing approximately 2 × 10^4^ cells was harvested from the culture wells. The different drugs and preservatives to be tested were diluted 10-, 20-, 100-, 1,000-, and, when necessary, 10,000-fold with phosphate buffered saline before being added to the cells in culture. Cell viability was determined after 48 h incubation in the presence of the test solutions using the 3-(4,5-dimethyl-2 thiazoyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay (Sigma, St Louis, MO, USA), a quantitative colorimetric measure of mitochondrial activity as an index of cell viability and proliferation. Absorbance was read on a spectrophotometer (Benchmark Microplate Reader; Bio-Rad, Hercules, CA, USA). The MTT assay detects living cells only and the signal generated is directly proportional to the number of live cells. The viability of cells in test solutions was calculated as a percentage of cells incubated in growth medium without test solution. Experiments were repeated between eight and 16 times and the results are given as the mean ± standard deviation (SD).

Because the results of preliminary experiments indicated that viability increased markedly in solutions that had been diluted 20-fold or more and the differences among the drugs were evident enough in 10-fold diluted solutions, we expressed the results as a cell viability score (CVS50), a number of cell lines with viability ≥50% in the presence of a 10-fold dilution of the drug, to enable easy comparison of the effects of different drugs. This concept is similar to the MIC~50~ (ie, the minimum inhibitory concentration of a drug required to inhibit the growth of 50% of organisms).

The antibiotic and anti-inflammatory drugs evaluated in the present study are listed in [Table 1](#t1-opth-4-1019){ref-type="table"}. The ophthalmic solution preservatives tested in the present study were 0.01% BAK (Wako Pure Chemical Industries, Osaka, Japan), 0.5% chlorobutanol (Wako), 1.0% polysorbate 80 (Tween 20; ICN Biomedicals, Aurora, OH, USA), 0.04% methyl paraoxybenzoate (Wako), and 0.04% propyl paraoxybenzoate (Wako). All preservatives were tested at commonly used concentrations.

Results
=======

For all cell lines tested, cell viability after exposure to cefmenoxime was ≥80% ([Figure 1](#f1-opth-4-1019){ref-type="fig"}). Cell viability after exposure of cells to the fluoroquinolones was concentration dependent, with ≥80% viability observed for solutions diluted 100-fold or more. Fluoroquinolones had less cell viability than the others except for tosufloxicin. Low toxicity was observed for betamethasone-containing drugs without BAK or polysorbate as the preservative ([Figure 2](#f2-opth-4-1019){ref-type="fig"}). The cell viability of the other anti-inflammatory drugs was clearly concentration dependent. BAK-containing anti-inflammatory drugs had less cell viability than the drugs without BAK. Nonsteroidal anti-inflammatory drugs had less cell viability than fluoromethorone with same concentration of BAK.

Using CVS50 as an indicator of cytotoxicity, the order of cell viability after exposure to the antibiotic solutions was determined to be cefmenoxime ≥ tosufloxicin ≥ dibekacin ≥ levofloxacin ≥ norfloxacin = gatifloxacin = moxifloxacin ([Table 1](#t1-opth-4-1019){ref-type="table"}), whereas that for the anti-inflammatory drugs was betamethasone ≥ betamethasone + fradiomycin \> preservative-free diclofenac ≥ preservative-free bromfenac \>\> 0.02% fluoromethorone ≥ 0.1% fluoromethorone = diclofenac + preservative (Diclod) = bromfenac + preservative (Bronuck) = pranoprofen ([Table 2](#t2-opth-4-1019){ref-type="table"}). The calculated CVS50 of the antibiotics ranged between one and four, whereas that of anti-inflammatory drugs preserved with BAK and Diclod was zero. These data are consistent with the results presented in [Figures 1](#f1-opth-4-1019){ref-type="fig"} and [2](#f2-opth-4-1019){ref-type="fig"}, which indicate that cell viability after exposure to antibiotics was generally higher than after exposure of cells to anti-inflammatory drugs.

Of the preservatives tested, BAK and polysorbate were cytotoxic to all cell lines ([Figure 3](#f3-opth-4-1019){ref-type="fig"}). Propyl paraoxybenzoate exhibited cytotoxicity only in the SIRC and conjunctival cell lines, whereas chlorobutanol and methyl paraoxybenzoate did not exhibit any cytotoxic effects.

Discussion
==========

The fluoroquinolones are broad-spectrum antibiotics that are the most commonly used drugs for the pre- and postoperative control of infection after eye surgery. In the present study, cefmenoxime, dibekacin, and tosufloxacin appeared to be the least cytotoxic. These results are partially consistent with those of a previous study performed in a single cell line[@b11-opth-4-1019] and support previous reports that levofloxacin is less toxic than moxifloxacin[@b12-opth-4-1019] or gatifloxacin.[@b13-opth-4-1019] Many previous studies evaluating the cytotoxicity of fluoroquinolones have used solutions preserved with BAK,[@b14-opth-4-1019],[@b15-opth-4-1019] which had a significant effect on the results. However, in the present study we were able to evaluate the toxicity of the pharmaceutical components of the ophthalmic solutions because we used preservative-free fluoroquinolone solutions. The results of the present study indicate that antibiotics are more toxic to conjunctival cells than to corneal cells, except for cefmenoxime, which was not cytotoxic against any of the cell lines used.

Dose-dependent cytotoxicity was observed for all anti-inflammatory drugs preserved with BAK in all cell lines. The corneal toxicity of preservative-containing solutions of diclofenac[@b16-opth-4-1019]--[@b18-opth-4-1019] and bromfenac[@b19-opth-4-1019] has already been documented and the present study further revealed that preservative-free diclofenac and bromfenac exhibit considerable toxicity. Pranoprofen preserved with BAK exhibited the greatest toxicity, although this may be due to the fact that this solution contained the highest concentration of BAK. Of the actual preservatives evaluated in the present study, the cytotoxic effects of BAK, polysorbate,[@b8-opth-4-1019] and cholorobutanol[@b9-opth-4-1019] were comparable to those reported previously; both methyl paraoxybenzoate and chlorobutanol exhibited significant cytotoxic effects at high concentrations.[@b10-opth-4-1019]

On the basis of the results of the present study, it is likely that any postoperative epithelial damage may be caused primarily by anti-inflammatory drugs because the cell viability determined in the present study for the routinely used nonsteroidal anti-inflammatory drugs (ie, Diclod and Bronuck) were very low compared with values determined for the antibiotics. CVS50 was demonstrated to be a useful system for comparisons of the cytotoxicity of different ophthalmic solutions, as evidenced by comparable results for MTT assay using multiple cell lines and various drug concentrations. In addition, we calculated another number \[(number of cell lines with viability \>80%) -- (number of cell lines with viability \<40%)\] for each drug at a 10-fold dilution based on the cell viability of different cell lines and the order of this number for tested solution was the same as that for CVS50. Considering biological fluctuations in cellular reaction to the drugs, we have to be careful of evaluation of the value of cell viability and the method for expressing general trend such as CVS50 may be one of the solutions.

The limitations of the present study include the use of bioassays only to evaluate cytotoxicity and the relatively long exposure time. However, the standardization of methods to evaluate the toxicity of ophthalmic solutions is still under development and the cytotoxic and/or ocular toxic effects of drugs clearly need to be evaluated more comprehensively. In the present study, we attempted to address these issues by evaluating the effects of a range of drug concentrations in four commercially available cell lines. We were able to compare the cytotoxic effects of the drugs easily using the CVS as well as graphically by plotting cell viability against drug concentration. With regard to exposure time, optimal exposure times for *in vitro* cell culture systems have not yet been established. It is common to use 48 h exposure followed by 48 h recovery in *in vitro* cytotoxicity assays; however, epithelial cells proliferate rapidly and further studies in epithelial cells are needed using shorter exposure times.

Conclusion
==========

In conclusion, the toxicity of a wide range of BAK-free ophthalmic solutions used postoperatively to control infection and inflammation was evaluated in four ocular surface cell lines. Because sufficient data regarding cell viability from multiple cell lines with different drug concentrations were available, the results of the MTT assay were expressed as CVS to enable the simple comparison of drug effects. The cytotoxicity of antibiotics was found to be dependent on the pharmaceutical components of the solution, whereas the toxicity of anti-inflammatory drugs was found to be dependent on both the pharmaceutical components of the solution and the preservative used. Based on the results of the present study, postoperative drug-induced epitheliopathy is most likely due to the effects of anti-inflammatory drugs.
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![Effects of antibiotic ophthalmic solutions on the viability of cultured rabbit corneal epithelial cells (RC-1 and SIRC), bovine corneal epithelial cells (BCE), and human conjunctival cells (Chang) after 48 h exposure. Data are the mean ± SD. Cefmenoxime was the least toxic. The cell viability score was determined and the order of cell viability was cefmenoxime ≥ tosufloxicin ≥ dibekacin ≥ levofloxacin ≥ norfloxacin = gatifloxacin = moxifloxacin ([Table 1](#t1-opth-4-1019){ref-type="table"}).](opth-4-1019f1){#f1-opth-4-1019}

![Effects of anti-inflammatory ophthalmic solutions on the viability of cultured rabbit corneal epithelial cells (RC-1 and SIRC), bovine corneal epithelial cells (BCE), and human conjunctival cells (Chang) after 48 h exposure. Data are the mean ± SD. Data for benzalkonium chloride (BAK)-free drugs are indicated by the dotted lines. Cell viability was greater in all BAK-free solutions, except for Diclod, compared with solutions containing BAK. The cell viability score was determined and the order of viability was betamethasone ≥ betamethasone + fradiomycin \> preservative-free diclofenac ≥ preservative-free bromfenac \>\> 0.02% fluoromethorone ≥ 0.1% fluoromethorone = diclofenac + preservative (Diclod) = bromfenac + preservative (Bronuck) = pranoprofen.](opth-4-1019f2){#f2-opth-4-1019}
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###### 

Antibiotic ophthalmic solutions evaluated in the present study

  **Active component**   **Trade name**                                                                                   **Preservative**                                                           **CVS50[\*](#tfn2-opth-4-1019){ref-type="table-fn"}**
  ---------------------- ------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------- -------------------------------------------------------
  Levofloxacin (0.5%)    Cravit (Santen, Osaka, Japan) Quixin (in US; Vistakon, Jacksonville, FL, USA; with 0.005% BAK)   No                                                                         3
  Moxifloxacin (0.5%)    Vigamox (Alcon, Fort Worth, TX, USA)                                                             No                                                                         1
  Gatifloxacin (0.3%)    Gatiflo (Senju, Osaka, Japan) Zymar (in US; Allergan, Irvine, CA, USA; with 0.005% BAK)          No                                                                         2
  Norfloxacin (0.3%)     Noflo (Banyu, Tokyo, Japan)                                                                      No                                                                         2
  Tosufloxacin (0.3%)    Tosuflo (Nitto, Nagoya, Japan)                                                                   No                                                                         3
  Dibekacin (0.5%)       Panimycin (Meiji, Tokyo, Japan)                                                                  No                                                                         3
  Cefmenoxime (0.5%)     Bestron (Kaken, Tokyo, Japan)                                                                    0.026% methyl paraoxybenzoate, 0.014% propyl paraoxybenzoate, boric acid   4

**Notes:**

Number of cell lines with viability ≥50% in the presence of a 10-fold dilution of the drug.

**Abbreviation:** BAK, benzalkonium chloride.

###### 

Anti-inflammatory ophthalmic solutions evaluated in the present study

  **Active component**                         **Trade name**                                                                                          **Preservative**                                             **CVS50[\*](#tfn5-opth-4-1019){ref-type="table-fn"}**
  -------------------------------------------- ------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ -------------------------------------------------------
  Betamethasone (0.1%)                         Rinderon (Shinogi, Osaka, Japan)                                                                        0.05% methyl paraoxybenzoate, 0.02% propyl paraoxybenzoate   4
  Betamethasone (0.1%) + fradiomycin (0.35%)   Rinderon A (Shionogi)                                                                                   Same as Rinderon                                             4
  Fluoromethorone (0.1%)                       Flumethoron 0.1% (Santen, Osaka, Japan)                                                                 0.005% BAK, polysorbate 80,                                  0
  Fluoromethorone (0.02%)                      Flumethoron 0.02% (Santen)                                                                              0.005% BAK, polysorbate 80                                   0
  Diclofenac (0.1%)                            Diclod (Wakamoto, Tokyo, Japan) Voltaren Ophthalmic Solution (in US; Novartis, East Hanover, NJ, USA)   Chlorobutanol, polysorbate 80, boric acid                    0
  Preservative-free diclofenac                 No brand name (experimental use only)                                                                   No                                                           1
  Bromfenac (0.1%)                             Bronuck (Senju, Osaka, Japan) Xibrom (in US; ISTA Pharmaceuticals, Irvine, CA, USA)                     0.005% BAK, polysorbate 80                                   0
  Preservative-free bromfenac                  No brand name (experimental use only)                                                                   No                                                           3
  Pranoprofen (0.1%)                           Niflan (Senju)                                                                                          0.007% BAK, polysorbate 80, boric acid                       0

**Notes:**

Number of cell lines with viability ≥50% in the presence of a 10-fold dilution of the drug.

**Abbreviation:** BAK, benzalkonium chloride.
